Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | OAT | P04181 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18302606 | 1.00 | CA1 (0.37) | CA1CA9SMN1; SMN2POLBLMNA | |
| SCHEMBL14249431 | 0.94 | POLB (0.39) | CA1CA9SMN1; SMN2POLBLMNA | |
| SCHEMBL12212 | 0.86 | — | — | |
| SCHEMBL12268 | 0.86 | — | — | |
| SCHEMBL12219 | 0.86 | — | — | |
| Iodide SCHEMBL10698321 | 0.84 | CA1 (0.43) | CA1CA9SMN1; SMN2LMNATSHR | |
| Hydrochloric Acid SCHEMBL1372283 | 0.84 | CA1 (0.43) | CA1CA9SMN1; SMN2LMNATSHR | |
| Hydrochloric Acid SCHEMBL1372279 | 0.84 | CA1 (0.43) | CA1CA9SMN1; SMN2LMNATSHR | |
| SCHEMBL3628734 | 0.81 | CA1 (0.40) | CA1CA9SMN1; SMN2CYP2D6 | |
| SCHEMBL8188297 | 0.78 | CA1 (0.40) | CA1CA9SMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | claimed |
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-107980042-B | Aryldihydro-2H-benzo [ b ] [1,4] oxazine sulfonamides and related compounds as ROR gamma agonists and for the treatment of disease | 莱斯拉公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2020-04-07 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190135768-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-09 | — | — | US | disclosed |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-09-20 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| EP-3307738-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| EP-3140291-A2 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016201225-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135768-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | CA1 1979/4885CA9 1822/4885SMN1; SMN2 1782/4885 |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | CA1 2749/4885CA9 3164/4885SMN1; SMN2 2085/4885 |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | CA1 2315/4885CA9 2112/4885SMN1; SMN2 2390/4885 |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | CA1 2128/4885CA9 2520/4885SMN1; SMN2 1570/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | CA1 2353/4885CA9 2723/4885SMN1; SMN2 2195/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | CA1 2353/4885CA9 2723/4885SMN1; SMN2 2195/4885 |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | CA1 2128/4885CA9 2520/4885SMN1; SMN2 1570/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | CA1 2128/4885CA9 2520/4885SMN1; SMN2 1570/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | CA1 2256/4885CA9 1936/4885SMN1; SMN2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.